Abstract 586P
Background
This study examines the impact of physical comorbidity on treatment and quality of life in rural oncology patients over 65.
Methods
Quantitative data was obtained using standardized questionnaires and assessment tools to gather information regarding patients’ sociodemographic details, cancer diagnosis, treatment access, commencement and completion, and quality of life (QoL). Descriptive analysis was undertaken to understand participant characteristics, rurality, and cancer-related details at baseline using frequencies and cross-tabulations; and further analysis was undertaken to examine the relationship between comorbidity and cancer outcome; and comorbidity and QoL. The qualitative component of the study adopted an approach comprising Focus Group Discussions to gather in-depth information and perspectives from patients, caregivers, and health professionals on the barriers and challenges faced in accessing cancer treatment in a rural context.
Results
Participants in the focus groups identified travel to larger regional centres and/or metropolitan areas and related arrangements as primary challenges to accessing diagnostic tests, surgeries, some treatments, and follow-up tests. Quantitative analysis revealed that the majority of the study population reported 2-6 comorbidities and COPD was the most prevalent comorbidity. An overall reduction in QoL was observed on comparison between QoL at baseline and post- cycle 4 of treatment. Patients with higher comorbidity burden experienced a greater negative impact on their QoL following 4 cycles of cancer treatment. Examination of the relationship between comorbidity and cancer outcome revealed disease progression in patients with higher comorbidity burden than those with lower comorbidity burden.
Conclusions
The study suggests the need for frequent monitoring and screening of geriatric cancer patients, to enhance outcomes of treatment and contribute to improvement of HRQoL in geriatric cancer patients living in rural and regional locations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.